![]() |
市场调查报告书
商品编码
1764940
2031年亚太地区生物製剂市场预测 - 区域分析 - 按产品、应用、来源和製造Asia Pacific Biologics Market Forecast to 2031 - Regional Analysis - by Product, Application, Source, and Manufacturing |
2023 年亚太生物製剂市场价值为 1,015.905 亿美元,预计到 2031 年将达到 4,170.829 亿美元;预计 2023 年至 2031 年的复合年增长率为 19.3%。
发展中地区生物技术发展推动亚太生物製剂市场
现代生物技术的许多应用都需要抗体,从基础研究到创新的医学治疗方法。治疗性抗体的开发为治疗各种疾病开闢了新的途径,证明了这些粒子的转化能力。抗体在诊断中也至关重要,因为它们提供了准确可靠的疾病识别方法。各国政府的支持日益增多、公私合作伙伴关係日益加强、疾病状况的不断变化以及资金活动的不断增加,正在广泛提升亚太地区、南美洲和中美洲以及中东和非洲等地区生物技术产业的业绩。阿联酋、沙乌地阿拉伯、阿曼、马斯喀特、巴林、台湾、马来西亚、印度、中国大陆、新加坡和日本等国家和地区是生物技术产业利润丰厚的市场。生物技术、遗传学和细胞生物学的进步有助于发现多种潜在的标靶治疗药物。生物技术是中国的战略产业。 「中国製造2025」计画强调支持高科技产品(包括创新药物)製造的研发能力。该计划旨在引导中国製药公司瞄准特定领域,以促进生物技术创新并提升出口。亚洲国家更注重利用基因组学、蛋白质组学和生物标记方面的进步进行诊断和治疗。因此,发展中地区生物技术产业的持续发展预计将在未来几年为生物製剂市场创造机会。
亚太生物製剂市场概览
亚太地区的生物製剂市场分为中国、日本、印度、韩国、澳洲和亚太其他地区。该地区的市场成长得益于大量患有遗传疾病的患者以及各国政府对医疗研发投入的增加。在过去几年中,中国人们对生物製剂益处的认识显着提高。此外,当地获得细胞株表征的各种测试服务的管道也有所增加,许多产品从临床前开发到商业化都有所发布,这对市场的成长产生了积极的影响。近年来,科学家和卫生当局致力于强调如何有效利用生物製剂来研究和治疗疾病以及开发药物和医疗器材。他们也努力加强对先天性残疾发展机制的认识。三星生物製剂公司已与中国生物技术公司 GeneQuantum Healthcare 签署合作协议,共同开发用于治疗非小细胞肺癌 (NSCLC)、三阴性乳癌 (TNBC) 和其他实体肿瘤的抗体药物偶联物 (ADC)。
亚太地区生物製剂市场收入及预测(2031年)(百万美元)
亚太地区生物製剂市场细分
亚太生物製剂市场分为产品、应用、来源、製造和国家。
根据产品类型,亚太生物製剂市场细分为单株抗体、疫苗、重组荷尔蒙/蛋白质、细胞和基因疗法以及其他。单株抗体在2023年占据了最大的市场。
从应用角度来看,亚太生物製剂市场主要分为癌症、传染病、自体免疫疾病等。 2023年,癌症领域占据了最大的市场。
依来源划分,亚太生物製剂市场分为哺乳动物生物製剂和微生物生物製剂。 2023年,哺乳动物生物製剂市场占有较大份额。
根据製造方式,亚太生物製剂市场分为外包和内部製造。 2023年,外包部分占据了更大的市场。
依国家划分,亚太生物製剂市场分为中国、印度、日本、韩国、澳洲和亚太其他地区。 2023年,中国占据了亚太生物製剂市场的主导地位。
AbbVie Inc、辉瑞公司、三星生物製品有限公司、ADMA Biologics, Inc.、无锡生物製品有限公司、Catalent Inc、AGC Biologics AS、阿斯利康公司、安进公司、Nitto Avecia 和 Quality Assistance sa 是亚太生物製剂市场的一些领先公司。
The Asia Pacific biologics market was valued at US$ 1,01,590.5 million in 2023 and is expected to reach US$ 4,17,082.9 million by 2031; it is estimated to register a CAGR of 19.3% from 2023 to 2031.
Evolution of Biotechnology in Developing Regions Fuels Asia Pacific Biologics Market
Antibodies are required in numerous applications in modern biotechnology, from fundamental research to innovative medical therapeutic approaches. The development of therapeutic antibodies has opened new avenues in treating various diseases, demonstrating the transformative ability of these particles. Antibodies are also crucial in diagnostics as they provide accurate and reliable approaches to disease identification. Growing support from governments, rising public-private partnerships, continuously changing disease profiles, and increasing funding activities are widely enhancing the performance of biotechnology industries in the regions such as Asia Pacific, South & Central America, and the Middle East & Africa. Countries such as the UAE, Saudi Arabia, Oman, Muscat, Bahrain, Taiwan, Malaysia, India, China, Singapore, and Japan are among the most lucrative markets for the biotechnology industry. Advancements in biotechnology, genetics, and cell biology have contributed to the identification of several potential therapeutics for targeted treatments. Biotechnology is a strategic sector for China. The Made in China 2025 initiative emphasizes on research capabilities supporting the manufacturing of high-tech products, including innovative medicines. The plan introduced Chinese pharmaceutical companies to target areas to spur biotechnology innovation and enhance exports. Asian countries are more focused on using genomics, proteomics, and biomarker advancements for diagnostic and therapeutic applications. Therefore, the ongoing developments in the biotechnology industry in developing regions are expected to create opportunities for the biologics market in the coming years.
Asia Pacific Biologics Market Overview
The biologics market in Asia Pacific is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The market growth in the region is driven by a large pool of patients living with genetic conditions and increasing investments in healthcare R&D by governments of respective countries. Over the past few years, there has been a significant rise in awareness about the benefits of biologics in China. Moreover, there was a rise in local access to a broad range of testing services for cell line characterization and many release from preclinical development to commercialization, creating a positive impact on the growth of the market. In recent years, scientists and health authorities have made efforts to highlight how biologics could be effectively utilized to study and treat diseases and develop pharmaceuticals and medical devices. They are also striving to strengthen their knowledge based on the mechanism of development of congenital disabilities. Samsung Biologics has signed a partnership agreement with China Biotech GeneQuantum Healthcare for the development of antibody-drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC), and other solid tumors.
Asia Pacific Biologics Market Revenue and Forecast to 2031 (US$ Million)
Asia Pacific Biologics Market Segmentation
The Asia Pacific biologics market is categorized into product, application, source, manufacturing, and country.
Based on product, the Asia Pacific biologics market is segmented into monoclonal antibodies, vaccine, recombinant hormones/proteins, cell and gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.
In terms of application, the Asia Pacific biologics market is categorized into cancer, infectious diseases, autoimmune diseases, and others. The cancer segment held the largest market share in 2023.
By source, the Asia Pacific biologics market is bifurcated into mammalian and microbial. The mammalian segment held a larger market share in 2023.
Based on manufacturing, the Asia Pacific biologics market is bifurcated into outsourced and in-house. The outsourced segment held a larger market share in 2023.
In terms of country, the Asia Pacific biologics market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific biologics market share in 2023.
AbbVie Inc; Pfizer Inc; Samsung Biologics Co Ltd; ADMA Biologics, Inc.; Wuxi Biologics Inc; Catalent Inc; AGC Biologics AS; AstraZeneca Plc; Amgen Inc; Nitto Avecia; and Quality Assistance s.a. are some of the leading companies operating in the Asia Pacific biologics market.